ARTICLE | Clinical News

Biogen ties anti-LINGO miss to non-linear dose response

September 16, 2016 7:00 AM UTC

Biogen Inc. (NASDAQ:BIIB) suggested a non-linear dose response to opicinumab ( BIIB033) could have led to the compound's failure to meet the primary endpoint in the Phase II SYNERGY study to treat relapsing forms of multiple sclerosis (MS). Biogen hopes the mAb against leucine-rich repeat neuronal protein 1 ( LINGO-1) can reverse the course of MS by allowing remyelination.

In June, opicinumab missed SYNERGY's composite primary endpoint, which evaluated the proportion of patients with a three-month improvement across four measures: ambulation as measured by the timed 25-foot walk (TW25) test; upper extremity function as evaluated by the 9-hole peg test; cognition as evaluated by the 3-second paced auditory serial addition test; and disability as measured by Expanded Disability Status Scale (EDSS) scores. ...